
lion tcr
Engineering T-Cells To Home In On Liver Cancer
Researchers in Singapore have selected, designed and engineered patient-specific T cells that target hepatitis B-infected liver cancer cells.

Lion TCR’s T-Cell Therapy Gets Phase I/II Trial Approval
Singapore’s Health Sciences Authority has approved Lion TCR’s Phase I/II clinical study of immunotherapy for liver cancer.
Lion TCR Raises US$20 Million In Series A Funding
The funds will be used to advance clinical trials of LioCyx™, Lion TCR’s T-cell therapy against hepatocellular carcinoma.
10 Of Singapore’s Hottest Biotech Startups
Check out these ten biomedical startups leading healthcare innovation from the little red dot.